In the 1st U19, we established panels of high specificity and high affinity monoclonal antibodies against the following human DC receptors: LOX-1, BDCA-2, DC-SIGN/L, Dectin-1, CD1d, DC-ASGPR, Langerin, CLEC-6, MARCO, CD40 and DCIR. These human DC receptor reagents uncovered fundamental new biology and were used for development of prototype vaccines that target antigens directly to DCs. Based on extensive efficacy data in vitro, as well as preliminary studies in two in vivo models, the Humouse and Rhesus macaque, we hypothesize that the most potent antigen-targeting vaccines will deliver multiple antigens, engage two receptors simultaneously, and will be directly linked to adjuvants. We envision three areas for improvement that are the basis of Aims 1-3.
In Aim 1, we will construct polyvalent vaccines composed of influenza viral hemagglutinin (HA), nucleoprotein (NP), and matrix protein2 (M2). Triple vaccines will induce broad repertoires of both cellular and humoral immune responses.
In Aim 2, we will generate vaccines that target two DC receptors to enhance the immunogenicity of vaccines.
In Aim 3, adjuvant-linked DC-targeting vaccines will be produced. The vaccines generated herein will undergo analysis of DC binding, activation, and internalization through Aim 4, and then undergo further studies within Projects 1-4. Projects 1 and 2 serve, through in vitro analysis, to discover the most potent candidate vaccines - particularly those that will evoke mucosal immunity. The selected vaccines will be tested thoroughly in vivo via Projects 3 and 4.

Public Health Relevance

Vaccine platforms generated and validated in this study will be tested in Project 1-4. Technology obtained in this study will be applied for the generation of vaccines tested in Phase I clinical trials in the near future.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-KS-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor Research Institute
United States
Zip Code
Yu, Chun I; Becker, Christian; Metang, Patrick et al. (2014) Human CD141+ dendritic cells induce CD4+ T cells to produce type 2 cytokines. J Immunol 193:4335-43
Banchereau, Romain; Baldwin, Nicole; Cepika, Alma-Martina et al. (2014) Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines. Nat Commun 5:5283
Chaussabel, Damien; Baldwin, Nicole (2014) Democratizing systems immunology with modular transcriptional repertoire analyses. Nat Rev Immunol 14:271-80
Joo, HyeMee; Li, Dapeng; Dullaers, Melissa et al. (2014) C-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses. Immunity 41:592-604
Alsina, Laia; Israelsson, Elisabeth; Altman, Matthew C et al. (2014) A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4. Nat Immunol 15:1134-42
Epaulard, Olivier; Adam, Lucille; Poux, Candice et al. (2014) Macrophage- and neutrophil-derived TNF-? instructs skin langerhans cells to prime antiviral immune responses. J Immunol 193:2416-26
Schmitt, Nathalie; Bentebibel, Salah-Eddine; Ueno, Hideki (2014) Phenotype and functions of memory Tfh cells in human blood. Trends Immunol 35:436-42
Duluc, Dorothée; Joo, HyeMee; Ni, Ling et al. (2014) Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1. J Immunol 192:5776-88
Mejias, Asuncion; Suarez, Nicolas M; Ramilo, Octavio (2014) Detecting specific infections in children through host responses: a paradigm shift. Curr Opin Infect Dis 27:228-35
Schmitt, Nathalie; Liu, Yang; Bentebibel, Salah-Eddine et al. (2014) The cytokine TGF-? co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. Nat Immunol 15:856-65

Showing the most recent 10 out of 87 publications